Photo by Michael Longmire on Unsplash
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.
As the world tries to combat widespread mental illness and addiction disorders, some scientists are looking to psychedelics for the treatment of the diseases.
Once a figure in the 1960s counterculture, psychedelics are reportedly gaining acceptance in mainstream medicine for the treatment of depression and anxiety as well as addiction and other mental disorders.
One such compound is ibogaine, a psychedelic substance found in the Western African shrub Tabernanthe iboga. While the psychedelic compound may have the potential to improve the quality of life for many people, the lack of accessibility to a reliable supply of pharmaceutical-grade ibogaine limits opportunities for research, product, and protocol development.
In addition to mental illness and addiction, therapeutic uses for ibogaine may include treatment for neuropathic pain, trauma, migraines, cluster headaches, and treatment-resistant mood disorders.
One of the few companies researching ibogaine is Mind Cure Health Inc. MCUR MCURF, a Vancouver, British Columbia-based life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health.
The Trip to Mainstream Treatment?
Earlier this year, MINDCURE announced The Ibogaine Project, a research and development program for manufacturing synthetic ibogaine and conducting preclinical explorations. By manufacturing pharmaceutical-grade ibogaine, MINDCURE plans to provide researchers and clinicians with a sustainable high-quality, and regulated supply of the compound to conduct studies and improve knowledge about its potential benefits.
Ibogaine has not entered mainstream treatment for the conditions it’s believed to help because its natural variability in plant form poses challenges for psychedelic drug research; there is limited access to a sustainable and consistent supply of ibogaine, and its cardiac toxicity and adverse effects need to be understood.
MINDCURE believes that its manufacturing of synthetic ibogaine comes at a time when the world desperately needs treatment for addiction and mood disorders. Weekly drug overdoses were as much as 45% higher in 2020 than in 2019, according to the U.S. Centers for Disease Control and Prevention.
The drug, alcohol, and other addictions treatment industry is projected to be worth $38.2 billion this year, and the global anxiety and depression market is expected to reach $24.4 billion by 2030. The cognitive enhancement market is estimated to reach $6.5 billion by the end of 2023.
Only a handful of companies are working with psychedelics to help solve addiction and mental health issues. Atai Life Sciences ATAI is developing several drugs based on psychedelic substances, including ibogaine and ketamine, and Mind Medicine MNMD is developing 3 clinical-stage programs, 2 of which focus on LSD and the 3rd on ibogaine.
The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.